Phase 1b Dose-Finding Study of Niraparib, Niraparib/Bevacizumab, Carboplatin-Paclitaxel, or Carboplatin-Paclitaxel/Bevacizumab in Combination With TSR-042 in Patients With Advanced or Metastatic Cancer

Trial Profile

Phase 1b Dose-Finding Study of Niraparib, Niraparib/Bevacizumab, Carboplatin-Paclitaxel, or Carboplatin-Paclitaxel/Bevacizumab in Combination With TSR-042 in Patients With Advanced or Metastatic Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Feb 2018

At a glance

  • Drugs Bevacizumab (Primary) ; Carboplatin (Primary) ; Niraparib (Primary) ; Paclitaxel (Primary) ; TSR 042 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors TESARO
  • Most Recent Events

    • 18 Dec 2017 New drug Bevacizumab has been added in the study. Hence there is a change in official title, purpose, primary endpoints and planned patient number. Treatment arm has been changed from 2 to 4.
    • 18 Dec 2017 Planned number of patients changed from 66 to 102.
    • 16 Oct 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top